ArticleScientific reports2026
Catechin-Folate nano-niosomes from Osbeckia parvifolia Arn. induce apoptotic cell death in Ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The current study establishes the mechanism on how dietary flavonoid, catechin fractions of Osbeckia parvifolia Arn. could be used as a therapeutic treatment for ovarian cancer, using a combination of network pharmacology, molecular validation and nano-formulations. From network modelling analysis, 420 protein targets linked to ovarian cancer, including five that act as major regulatory hubs - AKT1, STAT3, IL6, ESR1 and CASP3 were found. Catechin had the strongest binding affinity to all of these five hub proteins, especially for ESR1 (-11.089 kcal/mol) and AKT1 (-9.221 kcal/mol). In molecular dynamics simulation studies over 100 ns, catechin bonded strongly with its target proteins. HPLC guided fractionation (RT: 3.887 min) LC-MS/MS (RT:6.51 min), HPTLC (Rf: 0.973) were performed, which resulted in the confirmation of the presence of both catechin and epicatechin and verified the biosynthetic pathway of both through the measurement of the expression of their respective biosynthetic genes LAR (0.3637 folds) and ANR (0.2746 folds) in O. parvifolia. The evaluation of the six different nano-formulations of phytoniosomes led to F5 being the most stable with uniform spherical architecture, having an optimal particle size (229.2 nm), a high positive zeta potential (+ 42.7mV), and having the highest cytotoxicity (93.17%) in SKOV3 cells, the mechanism of action being through apoptosis induction and cell-cycle arrest. Hence, this study supports the hypothesis that catechin extracted from O. parvifolia can serve as an effective therapeutic candidate for the targeted treatment of ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.